Vaxcyte, Inc. (PCVX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Carlos, CA, United States. The current CEO is Grant E. Pickering.
PCVX has IPO date of 2020-06-12, 414 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $9.03B.
Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing novel protein vaccines to prevent and treat bacterial infectious diseases. The company's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine currently in Phase 1/2 clinical trials for invasive pneumococcal disease and pneumonia. Vaxcyte's pipeline also includes VAX-XP to address emerging strains and antibiotic resistance, VAX-A1 targeting Group A Strep, and VAX-PG designed to treat periodontitis. Founded in 2013 and headquartered in San Carlos, California, the company was formerly known as SutroVax, Inc. before rebranding in May 2020.
